QI
ANIK icon

QS Investors’s Anika Therapeutics ANIK Stock Holding History

QS Investors’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-300
Closed -$12K – 1196
2020
Q2 		$12K Hold
300
– – ﹤0.01% 1522
2020
Q1 		$9K Buy
300
+100
+50% +$4.04K ﹤0.01% 1525
2019
Q4 		$11K Buy
200
+100
+100% +$5.81K ﹤0.01% 1521
2019
Q3 		$6K Buy
+100
New +$5.13K ﹤0.01% 1587
2015
Q2 		– Sell
-16,109
Closed -$663K – 1406
2015
Q1 		$663K Sell
16,109
-31,793
-66% -$1.29M 0.01% 823
2014
Q4 		$1.95M Buy
+47,902
New +$1.87M 0.02% 590

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return

QS Investors's ANIK Position: Q3 2020 in Review

QS Investors sold out of Anika Therapeutics (ANIK) in Q3 2020, closing a stake of 300 shares — an estimated $12K sold.

QS Investors first reported a position in ANIK in Q4 2014 and held it in 6 quarters. The position peaked at $1.95M in Q4 2014. 156 funds tracked by Wall St. Rank hold ANIK as of Q3 2020.

  • QS Investors reported no remaining Anika Therapeutics position as of Q3 2020 after selling out during the quarter.
  • QS Investors sold 300 Anika Therapeutics shares in Q3 2020, an estimated $12K.
  • QS Investors first reported a position in Anika Therapeutics in Q4 2014 and held it in 6 quarters.
  • QS Investors's Anika Therapeutics position peaked at $1.95M in Q4 2014.
  • 156 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2020.

Based on QS Investors's 13F filing for Q3 2020, filed 12 Nov 2020.